Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

406
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
406
Human Genetics01:28

Human Genetics

1.3K
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
1.3K
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

182
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
182
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

114
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
114
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The response of human melanocytic nevi to simulated solar radiation assessed by single-nucleus RNA sequencing of frozen tissue.

The Journal of investigative dermatology·2026
Same author

Spectral EEG-guided adaptive neuromodulation for social anxiety disorder, performance-only subtype: a case report.

Frontiers in psychiatry·2026
Same author

Examining the Neural and Behavioral Impact of Accelerated Intermittent Theta Burst Stimulation in People with Opioid Use Disorder Who Smoke Tobacco Cigarettes: A Pilot Study.

Brain connectivity·2026
Same author

Transcranial Magnetic Stimulation (TMS) for Smoking Cessation in Cancer Survivors: A Path Forward.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Reward Deficiency Syndrome (RDS): A Common Neurogenetic Trait/State of All Addictions: Is this the new DSM?

British journal of healthcare and medical research·2026
Same author

Commentary on the Risks of Prescription GLP-1 Agonists in Patients on Psychiatric Medications.

Journal of psychiatric practice·2026

Related Experiment Video

Updated: Dec 31, 2025

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.5K

Pharmacogenomic Testing in Psychiatry: Ready for Primetime?

Gopalkumar Rakesh1, Calvin R Sumner2, Jeanne Leventhal Alexander3

  • 1Department of Psychiatry, University of Kentucky, Lexington, Kentucky.

The Journal of Nervous and Mental Disease
|January 3, 2020
PubMed
Summary

Pharmacogenomic testing in psychiatry shows strong analytical validity but lacks robust evidence for clinical efficacy. More research is needed before it can guide initial treatment plans.

More Related Videos

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.2K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.5K

Related Experiment Videos

Last Updated: Dec 31, 2025

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.5K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.2K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.5K

Area of Science:

  • Psychiatry
  • Genetics
  • Clinical Pharmacology

Background:

  • Pharmacogenomic testing is increasingly used in clinical psychiatry for treatment decisions.
  • Despite growing interest, robust evidence for its efficacy is limited.
  • Clinicians need a primer on the biological basis, benefits, and pitfalls of this testing.

Purpose of the Study:

  • To provide clinicians with an understanding of pharmacogenomic testing in psychiatry.
  • To review the biological underpinnings, evidence, and clinical decision-making challenges.
  • To discuss current relevance, patient communication, and future research needs.

Main Methods:

  • Review of existing evidence on pharmacogenomic testing in psychiatry.
  • Use of clinical vignettes to illustrate concepts.
  • Discussion of analytical validity, clinical validity, and utility.

Main Results:

  • Pharmacogenomic testing demonstrates strong analytical validity.
  • Clinical validity is modest, and evidence supporting clinical utility is minimal.
  • Current evidence does not support its use in leading initial treatment plans.

Conclusions:

  • More rigorous double-blinded randomized controlled trials are necessary.
  • Pharmacogenomic testing may serve an adjunct role but should not lead initial psychiatric treatment.
  • Further research is crucial to establish clinical utility and guide evidence-based practice.